To help countries achieve the maximum impact of new vaccines, the World Health Organization has released new guidance on how to introduce new vaccines in existing immunization programs.
Actavis picks Particle Sciences for generics development
Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant.
WuXi bets on anti-counterfeiting tech with an eye on drug safety
WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.
Government H5N1 vaccine orders drive jump in sales at Sinovac
At the start of 2014 the Chinese vaccine sector was rocked by the failure of three leading suppliers to obtain good manufacturing practice certification. Sinovac Biotech escaped unscathed from the rule tightening and this week posted a 17% jump in fourth-quarter sales.
AMRI bets on manufacturing with $41M Cedarburg buyout
AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
GVK plots a $16.5M Indian expansion as it dials up its global presence
Indian CRO GVK Biosciences is looking to boost its capabilities in contract manufacturing, planning to build a new plant in its home country while stretching its presence abroad.
Meet DPx, the result of a $2.6B CMO merger
A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year.
The seed strain is often to blame for low yields of vaccines to protect against pandemic flu strains H1N1 and H5N1, but Daiichi Sankyo has now encountered difficulties when processing the vaccine, leaving the drugmaker unable to hit the H5N1 vaccine production target it agreed upon with the Japanese government.
After a 'pivotal' year, AMRI expects another leap in 2014
Last year, Albany, NY, contract developer AMRI watched its founding CEO retire and its business model evolve, shifting its priorities to deliver a jump in revenue, and now the company believes it's on track for bigger growth in 2014.
UPDATED: Patheon soars in its last year as a public CMO
Contract manufacturer Patheon boosted its revenue by about 137% in the last fiscal year, hauling in more than $1 billion as it prepares to merge with competitor DSM.